Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck

Squamous Cell Carcinoma of Head and Neck

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Carcinoma, Hepatocellular

Uveal Melanoma

Diffuse Intrinsic Pontine Glioma, Ependymoma, Medulloblastoma, Recurrence

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms, Squamous Cell

Brain Neoplasms, Glioma

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

Lung Diseases, Interstitial

Turcot syndrome, Colorectal Neoplasms

Neoplasm Metastasis

Advanced Biliary Tract Cancer(BTC)

Carcinoma, Non-Small-Cell Lung

Advanced Kidney Cancer

Carcinoma, Renal Cell

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Carcinoma, Renal Cell

Neoplasms, Germ Cell and Embryonal, Pinealoma, Central Nervous System Neoplasms

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Post-Acute COVID-19 Syndrome, Carcinoma, Non-Small-Cell Lung

Clinical Trials

N'FORCE

NOCANO

VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma

ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma

PRiME II

Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

TORCH-OPTIMA

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

NOBLE

FLINN

The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.

IVE in mRCC

Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study

JACOB

SPRING

Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)

Perioperative Immunotherapy for NSCLC (ECTOP-1030)

Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC

LUNGVIR